PwPepwise

Liraglutide

Weight Loss

a.k.a. Saxenda · Victoza

Daily GLP-1 agonist

Liraglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone released from the gut after eating.

§Dosing at a glance

4 protocols · from the research
What it's forDoseHow oftenHowFor how long
Type 2 Diabetes (blood-sugar control)0.6 mgOnce dailySubcutaneousInjected just under the skin, into the fat layer.—
Chronic Weight Management (obesity, with or without type 2 diabetes)3.0 mgOnce dailySubcutaneousInjected just under the skin, into the fat layer.—
Prediabetes / Diabetes Prevention3.0 mgOnce dailySubcutaneousInjected just under the skin, into the fat layer.160 wks
Combination with exercise3.0 mgDaily——

Approximate values pulled from the research — double-check before dosing.

§01Summary

Liraglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone released from the gut after eating that helps regulate blood sugar, appetite, and body weight. By mimicking this hormone, liraglutide signals the pancreas to release insulin when blood sugar rises, suppresses appetite, and slows digestion — producing meaningful improvements across a range of metabolic conditions.

At a dose of 1.8 mg daily, liraglutide reduces blood sugar (HbA1c) more effectively than sulfonylureas and DPP-4 inhibitors in type 2 diabetes, while simultaneously producing weight loss and lowering blood pressure4,5,14. At a higher dose of 3.0 mg daily, liraglutide produces clinically meaningful weight loss in people with obesity — with over 63% of treated individuals losing at least 5% of body weight compared to 27% on placebo2 — and reduces the risk of developing type 2 diabetes in those with prediabetes by approximately 79% over three years11. In people with type 2 diabetes and established cardiovascular disease, liraglutide reduces the risk of cardiovascular death and all-cause mortality1. The drug also reduces composite kidney disease outcomes in people with type 2 diabetes3. The most common side effects are gastrointestinal — primarily nausea and diarrhea — which are typically mild to moderate and tend to diminish over time4,6.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Liraglutide is a long-acting acylated analog of human glucagon-like peptide-1 (GLP-1), sharing approximately 97% amino acid sequence homology with endogenous GLP-1(7-37). A C-16 fatty acid chain is attached via a glutamic acid linker to lysine at position 26 (K26), enabling non-covalent binding to albumin and dramatically extending the plasma half-life to approximately 13 hours — sufficient to support once-daily subcutaneous dosing compared to the minutes-long half-life of native GLP-11,2. This fatty acid modification also confers resistance to dipeptidyl peptidase-4 (DPP-4) proteolytic cleavage, the primary degradation pathway for endogenous GLP-1.

Liraglutide acts as a full agonist at the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed in pancreatic beta cells, cardiac tissue, kidney, brain, and vasculature. Upon binding, GLP-1R activates adenylate cyclase via Gs protein coupling, increasing intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA), which potentiates glucose-dependent insulin secretion from pancreatic beta cells. Critically, this insulinotropic effect is glucose-dependent, meaning insulin release is amplified only at elevated blood glucose concentrations — the primary mechanistic basis for the low hypoglycemia risk observed in clinical trials4,5. Liraglutide simultaneously suppresses glucagon secretion from pancreatic alpha cells in a glucose-dependent manner, further reducing postprandial hyperglycemia8.

Beyond the pancreas, liraglutide activates GLP-1R in the hypothalamus and brainstem, engaging appetite-suppressing neural circuits that reduce caloric intake and slow gastric emptying — together producing the sustained weight loss observed at both 1.8 mg and 3.0 mg doses2,6,7. The degree of weight loss is dose-dependent across the 1.2–3.0 mg range6. Reductions in systolic blood pressure of 4–7 mmHg observed across trials are thought to reflect a combination of weight loss, natriuretic effects, and direct vascular GLP-1R signaling8,9,10. GLP-1R activation in the kidney reduces tubular sodium reabsorption, contributing to observed reductions in albuminuria and composite renal outcomes3.

The cardiovascular mortality reduction observed in the LEADER trial (HR 0.78 for CV death)1 is not fully explained by glycemic or weight improvements alone. The survival benefit without statistically significant reductions in nonfatal MI or stroke suggests potential anti-inflammatory, anti-fibrotic, or anti-arrhythmic mechanisms at the cardiac GLP-1R level — an area of active mechanistic investigation. Conversely, the consistent increase in resting heart rate of approximately 7 bpm observed with liraglutide15,16 reflects sympathomimetic activity at cardiac GLP-1Rs, an effect that appears to be attenuated by concurrent aerobic exercise16 and that warrants particular attention in patients with pre-existing cardiac conduction pathology or reduced ejection fraction12,15. Liraglutide also improves multiple markers of beta-cell function including HOMA-B, C-peptide, and proinsulin-to-insulin ratio, suggesting potential preservation of beta-cell mass or function beyond acute secretagogue effects8.

§04Evidence & efficacy

Evidence base
270Studies
158Human
16Animal

Liraglutide has demonstrated robust, replicated efficacy across several distinct therapeutic areas in well-powered randomized controlled trials.

Glycemic control in type 2 diabetes: Liraglutide at 1.2–1.8 mg daily significantly reduces HbA1c by approximately 0.84–1.50% compared to sulfonylurea monotherapy5, by approximately 1.0% versus glimepiride added to metformin4, by approximately 1.33% versus insulin glargine on triple background therapy9, and by approximately 0.60 percentage points more than sitagliptin as add-on to metformin14. The 1.8 mg dose consistently outperforms 1.2 mg for glycemic reduction across the LEAD trial series4,5,9,10. Added to metformin and rosiglitazone, liraglutide reduces HbA1c by 1.5% compared to 0.5% with placebo8.

Weight management in obesity: Liraglutide 3.0 mg produces a mean weight loss of approximately 8.4 kg versus 2.8 kg with placebo (net difference −5.6 kg) over 56 weeks in non-diabetic individuals with obesity2, and 6.4 kg versus 2.2 kg in patients with type 2 diabetes7. Over 63% of treated individuals achieve ≥5% body weight loss2. Dose-dependent weight loss ranging from 4.8 kg (1.2 mg) to 7.2 kg (3.0 mg) versus 2.8 kg placebo has been demonstrated, with the 3.0 mg dose superior to orlistat6. Weight maintenance after initial diet-induced loss is also significantly improved by liraglutide 3.0 mg, with 81.4% maintaining ≥5% run-in weight loss versus 48.9% on placebo13. Combining liraglutide 3.0 mg with structured exercise produces the greatest total weight loss (−9.5 kg net vs. placebo) and exclusive improvements in insulin sensitivity and cardiorespiratory fitness16.

Diabetes prevention: Liraglutide 3.0 mg reduces the risk of type 2 diabetes onset in individuals with prediabetes and obesity by approximately 79% over 160 weeks (HR 0.21)11.

Cardiovascular outcomes: In patients with type 2 diabetes and established cardiovascular disease, liraglutide 1.8 mg reduces the primary composite MACE endpoint (HR 0.87), cardiovascular mortality by 22% (HR 0.78), and all-cause mortality by 15% (HR 0.85) versus placebo1.

Renal outcomes: Liraglutide reduces the composite renal endpoint by 22% relative to placebo in type 2 diabetes (HR 0.78), primarily driven by a 26% reduction in new-onset persistent macroalbuminuria3.

Obstructive sleep apnea: Liraglutide 3.0 mg significantly reduces apnea-hypopnea index by 12.2 versus 6.1 events/hour with placebo (treatment difference −6.1 events/h) at 32 weeks, with benefit significantly associated with degree of weight loss17.

Heart failure with reduced ejection fraction: Liraglutide does not improve clinical stability, cardiac function, or mortality in patients with advanced HFrEF12,15.

Pediatric obesity: Liraglutide 3.0 mg significantly reduces BMI standard-deviation score in adolescents with obesity versus placebo (estimated difference −0.22)20.

§05Safety

Liraglutide has been evaluated in large-scale, long-duration randomized controlled trials across multiple populations, providing a well-characterized safety profile.

Gastrointestinal effects are the most common adverse events across all doses and indications. Nausea occurs in 11–27% of liraglutide-treated individuals depending on dose and population4,14, with vomiting and diarrhea also reported at higher frequencies than placebo6,2. These effects are predominantly transient, mild to moderate in severity, and decline over time with continued treatment4.

Hypoglycemia risk is low when liraglutide is used without insulin or sulfonylureas, with rates comparable to placebo4,5. When combined with sulfonylureas, minor hypoglycemia rates are elevated relative to placebo though substantially lower than with sulfonylurea alone10. In type 1 diabetes, liraglutide increases symptomatic hypoglycemia rates and, at 1.8 mg, is associated with a significant increase in hyperglycemia with ketosis19.

Cardiovascular safety: In a large outcomes trial, liraglutide reduced cardiovascular mortality and was not associated with excess adverse cardiovascular events in patients with type 2 diabetes and established CVD1. However, in patients with advanced heart failure and reduced ejection fraction, liraglutide increases heart rate by approximately 7 bpm and is associated with a higher rate of serious cardiac adverse events (10% vs. 3% for placebo)15. A separate heart failure trial showed no significant benefit and a numerically higher rehospitalization rate (41% vs. 34%) with liraglutide12, supporting caution in HFrEF populations.

Pancreatitis: Incidence of pancreatitis was numerically lower in the liraglutide group than placebo in the LEADER cardiovascular outcomes trial1, and no cases of pancreatitis were reported in the 56-week SCALE Diabetes trial7.

Cholelithiasis: Gallstone formation was observed more frequently in the liraglutide monotherapy group compared to the combination exercise-plus-liraglutide group, suggesting physical activity may partially attenuate this risk16.

Serious adverse events occurred at modestly higher rates with liraglutide 3.0 mg versus placebo in long-term obesity trials (15% vs. 13%)11 and 6.2% vs. 5.0% in shorter 56-week studies2.

Anti-drug antibodies developed in approximately 9.8% of liraglutide-treated patients in one trial, without reported clinical significance9.

Pediatric safety: In adolescents, gastrointestinal adverse events occurred in 64.8% of liraglutide-treated participants versus 36.5% on placebo, and 10.4% discontinued due to adverse events. One suicide occurred in the liraglutide group, assessed as unlikely related to treatment, highlighting the importance of mental health monitoring in this population20.

§06History

Liraglutide emerged from research into the incretin system — the gut-derived hormonal axis that amplifies postprandial insulin secretion. Following the characterization of GLP-1 as a potent insulinotropic peptide in the late 1980s, interest in therapeutic exploitation was tempered by its very short plasma half-life (1–2 minutes) due to rapid DPP-4 degradation. Novo Nordisk scientists developed liraglutide in the 1990s by attaching a C-16 fatty acid to a modified GLP-1 backbone, enabling albumin binding and resistance to proteolysis, yielding a half-life compatible with once-daily dosing.

The pivotal LEAD (Liraglutide Effect and Action in Diabetes) clinical trial program, comprising six large Phase 3 RCTs, established liraglutide's efficacy and safety across multiple background therapy combinations in type 2 diabetes between 2008 and 20104,5,8,9,10,14. Liraglutide 1.2 mg and 1.8 mg (Victoza) received European Medicines Agency approval in 2009 and FDA approval in January 2010 for type 2 diabetes management.

The SCALE clinical program subsequently established the 3.0 mg dose for obesity management2,6,7,13, leading to FDA approval of liraglutide 3.0 mg (Saxenda) in December 2014 — the first GLP-1 receptor agonist approved specifically for chronic weight management. The landmark LEADER cardiovascular outcomes trial, published in 2016, demonstrated significant reductions in cardiovascular and all-cause mortality1, transforming liraglutide into a preferred therapy in type 2 diabetes patients with established cardiovascular disease per major guidelines. Subsequent analyses confirmed renal protective effects3 and efficacy in prediabetes populations11. FDA approval for adolescent obesity followed in 202020, further expanding its therapeutic scope.

§07References